Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amid Supply Concerns, EU Approves Gilead’s Remdesivir

Despite Controversy, Blockbuster Status Predicted

Executive Summary

Europe has granted a conditional approval to Gilead’s drug, now named Veklury, costing 2,000 per treatment.

You may also be interested in...



Remdesivir Should Give Gilead’s 2020 Revenue A Needed Lift

As it prepares to report second quarter earnings that may show coronavirus-related impacts, the company’s antiviral for COVID-19 may boost 2020 revenue and offset need for new products.

Quick Listen: Scrip’s Five Must-Know Things

Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.

Coronavirus Update: New Clinical Trials Network Could Help Pick Vaccine, Antibody Winners Faster

Plus: the World Health Organization has commissioned an independent panel to look at pandemic responses, while the emergence of an unknown pneumonia in Kazakstan is causing concern.

Related Content

Related Companies

UsernamePublicRestriction

Register

ID1132281

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel